The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

NCT00692263 Phase 4 COMPLETED

Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours. It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

Details

Lead sponsor	University of Southern Denmark
Phase	Phase 4
Status	COMPLETED
Enrolment	15
Start date	2008-02
Completion	2008-08

Conditions

• Healthy

Interventions

• escitalopram and tramadol
• placebo
• placebo and tramadol

Primary outcomes

• AUC of (+)-M1 metabolite of tramadol — 24 hours

Countries

Denmark